|
MEDICAL ADVOCATES
Adolescents
Teens   HAART/ART
General Reports 
Abacavir  
Atazanavir
Cabotegravir
Combivir
Darunavir
Dolutegravir
Etravirine
Efavirenz
Lopinavir
Nelfinavir
Nevirapine
Raltegravir
Rilpivirine
Ritonavir
Stavudine
Stribid
Tenofovir
Tenofovir/Emtricitabine
Tipranavir
Zidovudine 
Adherence

Adverse Events  
                  




 

HIV Management Main New/Newsworthy  Home Page  

Last Update: February 20, 2018
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

     Documents
 
  FULL-TEXT DOCUMENT
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
AIDS Info (USA)
April 16. 2015

Guidelines

      Journal Papers, Abstracts, and Commentaries
 

 
Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected with HIV in Early Life.
Unsal AB, Mattingly AS, Jones SE, et al
J Clin Endocrinol Metab. 2017 May
Abstract

Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.
Lazarus E, Nicol S, Frigati L, et al 
Pediatr Infect Dis J
. 2017 May;36(5):492-499
Abstract

Use of Unannounced Telephone Pill Counts to Measure Medication Adherence Among Adolescents and Young Adults Living With Perinatal HIV Infection.
Raymond JF, Bucek A, Dolezal C, et al

J Pediatr Psychol
. 2017 Mar 28
Abstract

Second and Third Line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.
Lazarus E, Nicol S, Frigati L, et al
Pediatr Infect Di
s J
. 2016 Dec 15.
Abstract

Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.
Gross IM, Hosek S, Richards MH, Fernandez MI.
AIDS Patient Care STDS. 2016 Jul;30(7):324-38.
Abstract

Phenotypic Co-receptor Tropism in Perinatally HIV-Infected Youth Failing Antiretroviral Therapy.
Agwu AL, Yao TJ, Eshleman SH, et al

Pediatr Infect Dis J
. 2016 Apr 13.

Abstract

Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
Dehority W, Abadi J, Wiznia A, Viani RM.

Drugs
. 2015 Aug 5.

Abstract

CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.
Fairlie L, Karalius B, Patel K,  et al
AIDS
. 2015 Jul 15
Abstract

Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study.
Kacanek D, Angelidou K, Williams PL, et al
AIDS. 2015 Jun 19;29(10):1227-1237.
Abstract

Acceptability and Feasibility of a Cell Phone Support Intervention for Youth Living with HIV with Nonadherence to Antiretroviral Therapy
Belzer ME, Kolmodin MacDonell K,  et al
AIDS Patient
Care STDS
. 2015 Apr 30.
Abstract

The sky is the limit": adhering to antiretroviral therapy and HIV self-management from the perspectives of adolescents living with HIV and their adult caregivers.
Denison JA, Banda H, Dennis AC, et al

J Int AIDS Soc
.
2015 Jan 13;18(1):19358
Abstract

Antiretroviral therapy in HIV-infected children and adolescents: lessons learned in 30 years of the epidemic.
Bazin GR, Gaspar MC, Silva NC,
Cad Saude Publica. 2014 Apr;30(4):687-702
Abstract

Factors Informing HIV Providers' Decisions to Start Antiretroviral Therapy for Young People Living With Behaviorally Acquired HIV.
Lee L, Rand CS, Ellen JM, Agwu AL.
 et al
J Adolesc Health
. 2014 Apr 29
Abstract

FULL-TEXT ARTICLE
Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012
Palladino C, Briz V, Bellón JM, et al
PLoS One
. 2014 May 1;9(5):e96307.
Paper

FULL-TEXT DOCUMENT
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group
of the Office of AIDS Research Advisory Council (OARAC) 

May 01, 2014
Paper

Once-Daily Antiretroviral Therapy in a Cohort of HIV-Infected Children and Adolescents.
Jiménez-Montero B, Beceiro J, de José-Gómez MI, et al
Pediatr Infect Dis J
. 2014 Apr 17
Abstract

Adrenal Enzyme Impairment in Neonates and Adolescents Treated with Ritonavir and Protease Inhibitors for HIV Exposure or Infection.
Kariyawasam D, Simon A, Laborde K,  et al
Horm Res Paediatr
. 2014 Feb 26
Abstract

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
Bwakura-Dangarembizi M, Kendall L, et al

N Engl J Med
. 2014 Jan 2;370(1):41-53
Abstract

Use of Nucleoside Reverse Transcriptase Inhibitor-only Regimens in HIV-infected Children and Adolescents.
Neely M, Rutstein R, Del Bianco G,  et al
Pediatr Infect Dis J. 2013 Sep;32(9):e370
Abstract

The initial feasibility of a computer-based motivational intervention for adherence for youth newly recommended to start antiretroviral treatment.
Outlaw AY, Naar-King S, Tanney M,  et al
AIDS Care
. 2013 Jul 22
Abstract

Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents.
Agwu AL, Fairlie L.
J Int AIDS Soc
. 2013 Jun 18;16:18579
Abstract

Social Ecological Predictors of Longitudinal HIV Treatment Adherence in Youth With Perinatally Acquired HIV.
Naar-King S, Montepiedra G, Garvie P, Kammerer B
J Pediatr Psychol. 2013 Apr 28.
Abstract

Feasibility of Interactive Text message Response (ITR) as a Novel, Real-Time Measure of Adherence to Antiretroviral Therapy for HIV+ Youth.
Dowshen N, Kuhns LM, Gray C, et al
AIDS Behav. 2013 Apr 2
Abstract

Health Literacy and Adherence to Antiretroviral Therapy Among HIV-Infected Youth.
Navarra AM, Neu N, Toussi S,
 et al
J Assoc Nurses AIDS Care
. 2013 Feb 21
Abstract

Predictors of Antiretroviral Medication Adherence Among a Diverse Cohort of Adolescents With HIV.
Chandwani S, Koenig LJ, Sill AM,  et al
J Adolesc Health. 2012 Sep;51(3):242-51
Abstract

Predictors of Highly Active Antiretroviral Therapy Utilization for Behaviorally HIV-1-Infected Youth: Impact of Adult Versus Pediatric Clinical Care Site.
Agwu AL, Siberry GK, Ellen J,  et al
J Adolesc Health. 2012 May;50(5):471-7.
Abstract

"+CLICK": pilot of a web-based training program to enhance ART adherence among HIV-positive youth.
Shegog R, Markham CM, Leonard AD, et al
AIDS Care
. 2011 Sep 8.
Abstract

Piloting behavioral family systems therapy to improve adherence among adolescents with HIV:A case series intervention study.
Gray W, Janicke D, Fennell E,  et al
J Health Psychol
. 2011 Mar 25|
Abstract

A primary care level algorithm for identifying HIV-infected adolescents in populations at high risk through mother-to-child transmission.
Ferrand RA, Weiss HA, Nathoo K, et al
Trop Med Int Health
. 2010 Dec 22.
Abstract

Enhanced CD8(+) T Cell Apoptosis in HIV-Infected Adolescents with Virologic Failure on Protease Inhibitor-Based Therapy.
Zuo J, Church J, Belzer M, et al 
AIDS Res Hum Retroviruses
. 2010 May 27.
Abstract

Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents.
Patel K, Ming X, Williams PL, Robertson KR, et al
 
AIDS
. 2009 Sep 10;23(14):1893-901.
Abstract

 

       Conference Reports, Abstracts, and Posters
 
 
Self-reported experience with financial incentives for virologic suppression among HIV-infected adolescents on antiretroviral therapy and guardians of HIV-infected pediatric and adolescent patients on antiretroviral therapy
N. Rakhmanina, K. Ganesan, A. Walters, et al
(XX International AIDS Conference)
Abstract
 

Abacavir
 

      Journal Papers, Abstracts, and Commentaries
 
 
Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.
Jesson J, Dahourou DL, Renaud F, et al
Lancet HIV. 2016 Feb;3(2):e64-75
Abstract

FULL-TEXT ARTICLE
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V, Musiime V, Kekitiinwa A,  et al 
Lancet Infect Dis
. 2015 Oct 5
Paper

FULL-TEXT ARTICLE
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis.

Adetokunboh OO, Schoonees A, Balogun TA, Wiysonge CS.
BMC Infect Dis. 2015 Oct 26;15(1):469.
Paper

FULL-TEXT PDF ARTICLE
Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol.
Adetokunboh OO, Schoonees A, Wiysonge CS.
Syst Re
v
. 2014 Aug 12;3(1):87.
Paper

Abacavir and Metabolite Pharmacokinetics in HIV-1-Infected Children and Adolescents.
Cross SJ, Rodman JH, Lindsey JC, et al  
J Acquir Immune Defic Syndr
. 2009 Mar 11
Abstract
 

Abacavir Pharmacokinetics During Chronic Therapy in HIV-1-Infected Adolescents and Young Adults.
Sleasman J, Robbins B, Cross S, et al 
Clin Pharmacol Ther. 2008 Dec 30
Abstract

      Conference Reports, Abstracts, and Posters

  24-month treatment outcomes amongst HIV-positive children and adolescent patients prescribed stavudine vs. abacavir
A.T. Brennan, M. Maskew, L. Long
(XX International AIDS Conference)
Abstract

Atazanavir
 

      Journal Papers, Abstracts, and Commentaries
 
 
Defining a cut-off for atazanavir in hair samples associated with virological failure among adolescents failing second-line antiretroviral treatment
Chawana TD, Gandhi M, Nathoo K, et al  
J Acquir Immune Defic Syndr. 2017 May 17.
Abstract

Pharmacokinetics of Unboosted Atazanavir in Treatment-Experienced HIV-infected Children, Adolescents and Young Adults.
Cressey TR, Hazra R, Wiznia A
,  et al
Pediatr Infect Dis J
. 2016 Aug 31.

Abstract

Long-Term Safety and Efficacy of Atazanavir-Based Therapy in HIV-Infected Infants, Children and Adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A.
Rutstein RM, Samson P, Fenton T,  et al
Pediatr Infect Dis J
. 2014 Sep 17.
Abstract

Population pharmacokinetics of atazanavir/r in HIV-1 infected children and adolescents.
Foissac F, Blanche S, Dollfus C, et al  
Br J Clin Pharmacol. 2011 Jun 8.
Abstract

Atazanavir and Atazanavir/Ritonavir Pharmacokinetics in HIV-Infected Infants, Children, and Adolescents.
Kiser JJ, Rutstein RM, Samson P, et al
AIDS
. 2011 May 21.
Abstract

HIV-Infected Adolescents: Relationship Between Atazanavir Plasma Levels and Bilirubin Concentrations.
Nso AP, Larru B, Bellón JM,  et al
J Adolesc Health
. 2011 Jan;48(1):100-2
'
Abstract


Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection -
Study ATN056.
Kiser JJ, Fletcher CV, Flynn PM, et al 
Antimicrob Agents Chemothe
r. 2007 Nov 19;

Abstract

Cabotegravir
 

      Journal Papers, Abstracts, and Commentaries
 
 
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli RKR, Back DJ, Rannard S,  et al  
Clin Pharmacokinet
. 2017 May  24
Abstract

Darunavir
 

      Journal Papers, Abstracts, and Commentaries
 
  Characteristics and early outcomes of children and adolescents treated with darunavir/ritonavir-, raltegravir- or etravirine-containing antiretroviral therapy in the Western Cape Province of South Africa.
Nuttall J, Pillay V.
S Afr Med J
. 2018 Feb 1;
Abstract

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
Cressey TR, Yogev R, Wiznia A, et al
J Pediatric Infect Dis So
c
. 2016 Apr 21
Abstract

Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1-infected Adolescents: Results From a Phase 2 Open-label Trial (DIONE).
Flynn P, Komar S, Blanche S,et al
Pediatr Infect Dis J
. 2014 Sep;33(9):940-5.
Abstract

High Dose of Darunavir in Treatment-Experienced HIV-Infected Adolescent Results in VirologicSuppression and Improved CD4 Cell Count.
Rakhmanina NY, Neely MN, Capparelli EV.

Ther Drug Monit
. 2012 Apr 30.
Abstract

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients.
Dobroszycki J, Abadi J, Wiznia AA, Rosenberg MG.
Adolesc Health Med Ther. 2011 Sep 14;2:85-93
Abstract

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents
Blanche S, Bologna R, Cahn P, et al 
AIDS
. 2009 Aug 30
Abstract

FULL-TEXT ARTICLE
Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.
Neely M, Kovacs A.
Ther Clin Risk Manag. 2009 Jun;5(3):595-615.
Paper

      Conference Reports, Abstracts, and Posters
 

 

Darunavir/r once daily in treatment-naïve adolescents: 48-week results of the DIONE study
C. Giaquinto, P. Flynn, S. Blanche, et a

(XIX International AIDS Conference)
Abstract


Dolutegravir
 
 

      Journal Papers, Abstracts, and Commentaries
 
 
Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-Experienced HIV-1 Infected Adolescents: 48-Week Results from IMPAACT P1093.
Viani RM, Alvero C, Fenton T, et al
Pediatr Infect Dis J. 2015 Aug 4.
Abstract

Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults.
McCormack PL.
Drugs
. 2014 Jul 9
Abstract


Efavirenz
 

      Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.
BREATHER (PENTA 16) Trial Group
Lancet HIV. 2016 Sep;3(9):e421-30
Paper

 

       Conference Reports, Abstracts, and Posters

  The predictability of NONMEM generated clearance values of efavirenz in South African children using CYP2B6 516 G>T polymorphism versus haplotype combinations (CYP2B6 515 G>T; 785 A>G and 983T>C) as covariates
M. Rheeders, R. Reay, M. Viljoen, C. Dandara
(XX International AIDS Conference)
Abstract

Etravirine
 

      Journal Papers, Abstracts, and Commentaries
 
  Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Tudor-Williams G, Cahn P, Chokephaibulkit K, et al
HIV Med
. 2014 Mar 3.
Abstract

Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
Königs C, Feiterna-Sperling C, Esposito S,  et al
AIDS
. 2011 Dec 7
Abstract


Lopinavir
 

      Journal Papers, Abstracts, and Commentaries
 
  Brief Report: Lopinavir Hair Concentrations are the Strongest Predictor of Viremia in HIV-infected Asian Children and Adolescents on Second-line Antiretroviral Therapy.
Pintye J, Bacchetti P, Teeraananchai S, et al
J Acquir Immune Defic Syndr
. 2017 Aug 18
Abstract

Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection.
Schenone E, Di Biagio A, Parisini A, et al
J Chemother. 2012;24(1):56-8.
Abstract

Pharmacokinetics of High-Dose Lopinavir/Ritonavir with and without Saquinavir or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors - Study PACTG P1038.
Robbins BL, Capparelli EV, Chadwick EG, et al
Antimicrob Agents Chemothe
r. 2008 Jul 14.
Abstract


Nevirapine
 

      Journal Papers, Abstracts, and Commentaries
 
  Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naïve Adolescents in Asia.
Boettiger DC, Sudjaritruk T, Nallusamy R,  et al
 J Adolesc Health
. 2016 Jan 20.
Abstract

Steady-State Pharmacokinetics of Nevirapine Extended-Release Tablets in HIV-1 Infected Children and Adolescents: An Open-Label, Multiple Dose, Cross-Over Study.
Giaquinto C, Anabwani G, Feiterna-Sperling C, et al 
Pediatr Infect Dis
J
. 2013 Dec 30.

Abstract


Raltegravir
 

     Journal Papers, Abstracts, and Commentaries
 
  Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years.
Nachman S, Zheng N, Acosta EP,  et al
Clin Infect Dis. 2014 Feb;58(3):413-2

Abstract

Pharmacokinetics, Safety and 48 Week Efficacy of Oral Raltegravir in Human Immunodeficiency Virus type-1 (HIV) infected Children 2
through 18 years of Age.

Nachman S, Zheng N, Acosta E,  et al
Clin Infect Dis
. 2013 Oct 21
Abstract

FULL-TEXT ARTICLE
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics.

Larson KB, King JR, Acosta EP.
Adolesc Health Med Ther. 2013 Aug 27;4:79-87
Paper

Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents.
Briz V, León-Leal JA, Palladino C,  et al
Pediatr Infect Dis J. 2012 Mar;31(3):273-277.
Abstract


Rilpivirine
 

      Journal Papers, Abstracts, and Commentaries
 
  In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli RKR, Back DJ, Rannard S,  et al  
Clin Pharmacokinet
. 2017 May  24
Abstract

Rilpivirine as a Treatment for HIV-infected Antiretroviral-Naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics
Lombaard J, Bunupuradah T, Flynn PM, et al
Pediatr Infect Di
s J
. 2016 Jun 10.
Abstract

Rilpivirine Pharmacokinetics Without and With Darunavir/ritonavir once daily in Adolescents and Young Adults.
Foca M, Yogev R, Wiznia A,
Pediatr Infect Dis J
. 2016 May 16.
Abstract


Ritonavir
 

      Journal Papers, Abstracts, and Commentaries
 
  Adrenal Enzyme Impairment in Neonates and Adolescents Treated with Ritonavir and Protease Inhibitors for HIV Exposure or Infection.
Kariyawasam D, Simon A, Laborde K,  et al
Horm Res Paediatr
. 2014 Feb 26
Abstract

Stavudine
 

      Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V, Musiime V, Kekitiinwa A,  et al 
Lancet Infect Dis
. 2015 Oct 5
Paper

      Conference Reports, Abstracts, and Posters

  24-month treatment outcomes amongst HIV-positive children and adolescent patients prescribed stavudine vs. abacavir
A.T. Brennan, M. Maskew, L. Long
(XX International AIDS Conference)
Abstract

Stribid
 

       Conference Reports, Abstracts, and Posters

  Safety, efficacy and pharmacokinetics of the once-daily integrase inhibitor -based stribild single-tablet regimen in HIV-infected treatment-naïve adolescents through 24 weeks of treatment
K. Chokephaibulkit, A. Gaur, J. Fourie, et al
(XX International AIDS Conference)
Abstract

Tenofovir
 

      Journal Papers, Abstracts, and Commentaries
 
 
Long-Term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1 Infected Adolescents Failing Antiretroviral Therapy: The Final Results of Study GS-US-104-0321.
Negra MD, De Carvalho AP, De Aquino MZ,  et al

Pediatr Infect Dis J
.
2015 Jan 16
Abstract

Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV.
Lucey JM, Hsu P, Ziegler JB.
BMJ Case Rep
. 2013 Jul 9;2013(jul08_2).
Abstract

Tenofovir Treatment Duration Predicts Proteinuria in a Multi-Ethnic United States Cohort of Children and Adolescents with Perinatal HIV-1 Infection.
Purswani M, Patel K, Kopp JB,  et al
Pediatr Infect Dis J
. 2012 Dec 17
Abstract

A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-Experienced Human Immunodeficiency Virus-1 Infected Adolescents.
Negra MD, de Carvalho AP, de Aquino MZ, et al
Pediatr Infect Dis J. 2012 Feb 1.
Abstract

FULL-TEXT PDF ARTICLE
Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Pontrelli G, Cotugno N, Amodio D,  et al
BMC Infect Dis. 2012 Jan 23;12(1):18.
Paper

Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults: A 60-Month Follow-Up Study.
Viganò A, Bedogni G, Manfredini V,  et al
Clin Drug Investig. 2011;31(6):407-15
Abstract

A Tailored Dose of Tenofovir Could Reduce Its Impact on Bone Mass in HIV Type 1-Infected Children and Adolescents: A Report from 5 Years of Clinical Experience.
Rosso R, Parodi A, Torrisi C, et al
AIDS Res Hum Retroviruses
.
2010 Sep 28
Abstract

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
Purdy JB, Gafni RI, Reynolds JC
J Pediatr. 2008 Apr;152(4):582-4.
Abstract

Increased beta-2 Microglobulinuria in HIV-1-Infected Children and Adolescents Treated with Tenofovir
Papaleo A, Warszawski J, Salomon R, et al

Pediatr Infect Dis J. 2007 Oct;26(10):949-951.

Abstract
 

       Conference Reports, Abstracts, and Posters
 
 

POSTER
Antiretroviral therapy of treatment-experienced perinatally HIV-1-positive adolescent patients transitioned to an adult HIV-care hospital: an ongoing challenge
E. Cordova, J. Yañez Garcia, C. Rodriguez, et al
(XIX International AIDS Conference)
Poster     Abstract


Tenofovir/Emtricitabine
 

      Journal Papers, Abstracts, and Commentaries
 
  Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.
Rudy BJ, Kapogiannis BG, Worrell C,  et al

J Acquir Immune Defic Syndr
. 2015 May 1;69(1):52-60.
Abstract

Tipranavir
 

      Journal Papers, Abstracts, and Commentaries
 
  Efficacy and Safety of Tipranavir Co-Administered with Ritonavir in HIV-1-Infected Children and Adolescents: 5 Years of Experience
Salazar JC, Cahn P, Negra MD,  et al
Pediatr Infect Dis J.
2013 Aug 29
Abstract

Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
Salazar JC, Cahn P, Yogev R, et al

AIDS. 2008 Sep 12;22(14):1789-98.
Abstract


Zidovudine
 

      Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V, Musiime V, Kekitiinwa A,  et al 
Lancet Infect Dis
. 2015 Oct 5
Paper

HAART Adverse Events
 

Immune Reconstitution Inflammatory Syndrome
 
      Journal Papers, Abstracts, and Commentaries
 
  Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.
Krogstad P, Patel K, Karalius B,. et al
AIDS
. 2015 Mar 27;29(6):683-693
Abstract

Immune Reconstitution Inflammatory Syndrome Associated With Progressive Multifocal Leukoencephalopathy in a Perinatally Acquired
Human Immunodeficiency Virus-Infected Young Adult
Chong TW, Dieudonne A.

Pediatr Infect Dis J. 2
007 Nov;26(11):1068-1070.
Abstract

Cutaneous

      Journal Papers, Abstracts, and Commentaries

  Cutaneous EBV-related lymphoproliferative disorder in a 15-year-old boywith AIDS: an unusual clinical presentation.
Fardet L, Blanche S, Brousse N, et al.

J Pediatr Hematol Oncol 2002 Nov;24(8):666-9
Abstract
 
 

Endocrine

Cushing's Syndrome

      Journal Papers, Abstracts, and Commentaries

 
Cushing Syndrome and Severe Adrenal Suppression Caused by Fluticasone and Protease Inhibitor Combination in an HIV-Infected Adolescent.
St Germain RM, Yigit S, Wells L, et al 

AIDS Patient Care STDS
. 2007 Jun;21(6):373-7.

Abstract

Ritonavir-Fluticasone Interaction Causing Cushing Syndrome in HIV-Infected Children and Adolescents.
Arrington-Sanders R, Hutton N, Siberry GK.
Pediatr Infect Dis J. 2006 Nov;25(11):1044-1048.
Abstract
 

Hepatic
 
      Journal Papers, Abstracts, and Commentaries
 
  Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy.
Gil AC, Lorenzetti R, Mendes GB, et al

Sao Paulo Med
J. 2007 Jul;125(4):205-209.
Abstract
 
Metabolic

      Journal Papers, Abstracts, and Commentaries

 
Evaluation of insulin resistance in a cohort of HIV-infected youth.
Rosso R, Parodi A, d'Annunzio G, Ginocchio F, et al
 
Eur J Endocrinol
. 2007 Nov;157(5):655-9.
Abstract

Hyperinsulinemia induced by highly active antiretroviral therapy in an adolescent with polycystic ovary syndrome who was infected with human immunodeficiency virus.
Vigano A, Manzoni P, Riva S,  et al.
  
Fertil Steril
2003 Feb;79(2):422-3
Abstract

Musculoskeletal

      Journal Papers, Abstracts, and Commentaries

  Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements.
Pitukcheewanont P, Safani D, Church J, Gilsanz V.

Osteoporos I
nt. 2005 Feb 9;
Abstract

Oral

      Journal Papers, Abstracts, and Commentaries

  Candida Epiglottitis in an Adolescent with Acquired Immunodeficiency Syndrome.
Sharma N, Berman DM, Scott GB, Josephson G.
Pediatr Infect Dis J. 2005 Jan;24(1):91-92
Abstract


HIV Management Main New/Newsworthy  Home Page  

Adolescent HIV/AIDS : HAART/ART